Today's Trend
AnaptysBio, Inc. (NASDAQ: ANAB) is seeing mixed analyst signals. The stock has increased recently, supported by a more favorable near-term earnings outlook and continued bullish ratings, but reductions to longer-term forecasts and price targets may limit upside.
- HC Wainwright improved near-term estimates: The firm raised its Q3 2026 forecast to breakeven from a $0.03-per-share loss and increased its FY2026 estimate to a $1.30 loss from a $2.60 loss. HC Wainwright maintained a Buy rating and a $95 price target, implying substantial potential upside from recent trading levels.
- Long-term profitability remains projected: Despite revisions, HC Wainwright still forecasts AnaptysBio turning profitable beginning in FY2027, with projected EPS rising to $6.50 by FY2030. This supports the investment case if the company’s pipeline and commercialization plans progress as expected.
- Leerink Partners remains bullish: Leerink lowered its price target from $90 to $81 but retained an Outperform rating, with the revised target still representing approximately 56.7% upside from the cited share price.
- Analyst consensus is favorable: AnaptysBio received an average Moderate Buy recommendation from analysts, indicating generally positive sentiment but not unanimous conviction. AnaptysBio Receives Average Recommendation of Moderate Buy
- Reported short interest was zero shares: The latest data show no reported short position and a zero-day days-to-cover ratio. This removes an apparent source of short-selling pressure, although the figure may reflect a reporting or data anomaly rather than a meaningful change in investor positioning.
- Longer-term earnings forecasts were reduced: HC Wainwright cut its FY2027, FY2028, FY2029 and FY2030 EPS estimates to $2.42, $4.57, $5.23 and $6.50, respectively. These reductions signal more cautious expectations for AnaptysBio’s future earnings growth.
- Leerink’s price-target cut is a cautionary signal: Although the firm maintained an Outperform rating, lowering its target to $81 suggests analysts see less upside than previously expected.